Fig 1 - uploaded by Nadia Tubiana-Rufi
Content may be subject to copyright.
Demonstrating cerebellar hypoplasia/aplasia in one of the original cases caused by PTFA1 mutation and described by the author. Taken from Hoveyda et al. [30] .

Demonstrating cerebellar hypoplasia/aplasia in one of the original cases caused by PTFA1 mutation and described by the author. Taken from Hoveyda et al. [30] .

Source publication
Article
Full-text available
Neonatal diabetes mellitus is rare. Typically, infants are of low birth weight and develop hyperglycemia requiring exogenous insulin within the first 6 weeks. Although pediatricians face numerous difficulties in managing insulin therapy at this age, very few data are available on possible methods of insulin delivery in neonatal diabetes. We report...

Contexts in source publication

Context 1
... of neonatal diabetes associated with cerebellar hypoplasia [30] . The 3 children of consanguineous, Paki- stani origin had dysmorphic features (low-set ears, triangular facies, talipes equin- ovarus and joint stiffness), associated with neonatal diabetes, microcephaly, recur- rent apnoeic attacks and absent cerebellar tissue on brain imaging ( fig. 1). A further child of North European descent was later identified with an identical phenotype in whom an autopsy demonstrated complete pancreatic agenesis. Further studies on this child and the original family led to the identification of the gene responsible, PTF1A. This gene encodes the pancreas transcription factor 1 which is ...
Context 2
... transcription factors, the genes Pdx1 and Ptf1a/p48, regulate the very early steps of pancreas development. The homeobox gene Pdx1/IPF1 is already expressed in the prepancreatic endoderm (E8.5-9) before any evidence of bud formation and persists in proliferating pancreatic epithelial cells at the bud stage ( fig. 1 a, b) and during sub- sequent branching of the epithelium [4,5] . During -cell development Pdx1 is later reexpressed in the mature -cell where it controls the transcription of the insulin gene in the adult pancreas [6] . Knocking out Pdx1 results in pancreas agenesis [5] . Pancreatic buds form but then stop their development and ...
Context 3
... Ptf1a-expressing cells and their progeny permanently express the -galactosidase gene and can thus be identified. This experiment revealed that Ptf1a is, like Pdx1, largely expressed at the early bud stage in uncommitted pancreatic progenitors ( fig. 1 c). Accordingly, fate mapping of these Ptf1a-expressing cells demonstrated that Ptf1a-positive cells give rise to endocrine, ductal and acinar cells. ...
Context 4
... although expression of dominant negative HNF1 in -cells results in a severe reduc- tion of -cell mass, overexpression of the wild-type version of HNF1 unexpectedly also results in a comparably severe phenotype [50,51] . We have measured the proportion of -cells relative to other pancreatic cells in very young (2-week-old) mice to circumvent possible confounding consequences of prolonged diabetes and metabolic abnormalities, and noted no major differences rel- ative to wild-type mice ( fig. 1 a). However, a clear reduction in the size of pancreatic islets was noted that is compensated by a larger number of extra-insular -cells or small clusters ( fig. 1 b, c). ...
Context 5
... have measured the proportion of -cells relative to other pancreatic cells in very young (2-week-old) mice to circumvent possible confounding consequences of prolonged diabetes and metabolic abnormalities, and noted no major differences rel- ative to wild-type mice ( fig. 1 a). However, a clear reduction in the size of pancreatic islets was noted that is compensated by a larger number of extra-insular -cells or small clusters ( fig. 1 b, c). We also measured proliferation rates in embryonic day 18.5 embryos, where blood glucose is normal in all genotypes, and in 3-month-old mice ( fig. 1 d-f). ...
Context 6
... a clear reduction in the size of pancreatic islets was noted that is compensated by a larger number of extra-insular -cells or small clusters ( fig. 1 b, c). We also measured proliferation rates in embryonic day 18.5 embryos, where blood glucose is normal in all genotypes, and in 3-month-old mice ( fig. 1 d-f). Although lower than average values were noted in Hnf1 -/--cells, this did not reach statistical significance ( fig. 1 d-f). ...
Context 7
... also measured proliferation rates in embryonic day 18.5 embryos, where blood glucose is normal in all genotypes, and in 3-month-old mice ( fig. 1 d-f). Although lower than average values were noted in Hnf1 -/--cells, this did not reach statistical significance ( fig. 1 d-f). ...
Context 8
... T antigen oncogene selectively in pancreatic -cells under the control of the rat insulin II promoter (Rip2- TAg) on either Hnf1 +/+ , Hnf1 +/-, or Hnf1 -/-backgrounds. As expected [52,53] , the Rip2-TAg transgene invariably caused insulinomas after 3 months of age on both Hnf1 +/+ and Hnf1 +/-backgrounds, and this led to hypoglycaemia and death ( fig. 1 d, e). However, on an Hnf1 -/-background the development of tumours was exceptional, it was observed only after 9 months, and tumour size at this time was more than 2-fold smaller than in Hnf1 +/+ or Hnf1 +/-littermates at 12 weeks ( fig. 1 d, e). Although sev- eral factors could theoretically account for such reduced tumourgenicity, ...
Context 9
... expected [52,53] , the Rip2-TAg transgene invariably caused insulinomas after 3 months of age on both Hnf1 +/+ and Hnf1 +/-backgrounds, and this led to hypoglycaemia and death ( fig. 1 d, e). However, on an Hnf1 -/-background the development of tumours was exceptional, it was observed only after 9 months, and tumour size at this time was more than 2-fold smaller than in Hnf1 +/+ or Hnf1 +/-littermates at 12 weeks ( fig. 1 d, e). Although sev- eral factors could theoretically account for such reduced tumourgenicity, it was found to be in part due to reduced proliferation. ...
Context 10
... sev- eral factors could theoretically account for such reduced tumourgenicity, it was found to be in part due to reduced proliferation. Thus, in situ analysis of pancreatic tissues revealed that Ki67 labelling was reduced by 3-fold in T-antigen-expressing -cells from Hnf1 -/-Rip2-TAg versus Hnf1 +/+ Rip2-TAg mice ( fig. 1 f). Furthermore, where- as explanted Hnf1 +/+ Rip2-TAg -cell lines exhibited a robust expansion in culture, dissected Hnf1 -/-Rip2-TAg tumour cells placed in culture showed a complete failure to grow ( fig. 1 g). ...
Context 11
... in situ analysis of pancreatic tissues revealed that Ki67 labelling was reduced by 3-fold in T-antigen-expressing -cells from Hnf1 -/-Rip2-TAg versus Hnf1 +/+ Rip2-TAg mice ( fig. 1 f). Furthermore, where- as explanted Hnf1 +/+ Rip2-TAg -cell lines exhibited a robust expansion in culture, dissected Hnf1 -/-Rip2-TAg tumour cells placed in culture showed a complete failure to grow ( fig. 1 g). These results thus show that HNF1 is essential for the proliferative response that is induced by the T antigen oncogene in -cells, and more generally they indicate that HNF1 controls cellular processes required for oncogenesis in -cells. ...
Context 12
... order to determine the exact mechanism of FGF10 effect, we next used culture experiments. The pancreases from E13.5 rat embryos were dissected as described previously [12,13,17] and as presented in figure 1 . The pancreases were cultured on filters at the air-liquid interface ( fig. 2 ). ...
Context 13
... MRI studies were non-informative concerning the differentiation between focal and diffuse HI but confirmed the localization of the [ 18 F]fluoro-L -DOPA in the pancreas. PET images showed that most of the radioactivity accumulated in the kid- neys and urinary bladder, the main elimination route of the radiotracer ( fig. 1 ). Con- sequently, the high radioactivity in these organs, particularly in the left kidney, might increase the difficulty in identifying focal forms localized in the tail of the pancreas when the PET images alone are interpreted. ...
Context 14
... 15 patients, a focal uptake of [ 18 F]fluoro-L -DOPA was observed in the pancre- atic area ( fig. 1 a). In these patients, the area of the suspected pancreatic abnormality, based on imaging diagnosis, was biopsied. ...
Context 15
... 39 children, a diffuse accumulation of [ 18 F]fluoro-L -DOPA ( fig. 1 b) was ob- served, and diffuse HI was suspected. Nine children were resistant to the medical treatment and were submitted to surgery. ...
Context 16
... heart cells and SUR2B in smooth muscle [6] . Kir6.2 subunit forms the channel pore in the majority of tissues such as pancreatic -cell, brain, heart and skeletal muscle [3] , while Kir6.1 can be found in smooth vas- cular muscle and astrocytes. These different channel forms have different pore prop- erties and adenine nucleotide sensitivity [3] ( fig. 1 ). The KCNJ11 and ABCC8 genes, encoding Kir6.2 and SUR1, are located at 11p15 [7] , close to the large IDDM2 linkage peak. The K ATP channels play multiple physiological roles in the regulation of glucose metabolism: insulin secretion by the pancreatic -cells, glucagon release by the pan- creatic -cells [8] , somatostatin secretion ...
Context 17
... The open- ing of K ATP channels exerts a strong suppressive effect on neuronal activity during hypoxia by shifting membrane potentials in the hyperpolarized direction [22] . Mice lacking Kir6.2 are extremely susceptible to generalized seizure after brief hypoxia and K ATP channels might therefore participate in a preconditioning-induced neuronal Fig. 1. Different K ATP channel forms and metabolic regulation. Several isoforms of either Kir and SUR subunits are found in the different organs and confer to the channels their specificity but all inter- fere with the glucose metabolism. The Kir6.2/SUR1 channels are found in neurons and the pancreas, whereas the Kir6.2/SUR2 channels are ...
Context 18
... marks then have to survive periods of extensive epigenetic repro- gramming of the genome during pre-implantation and post-implantation develop- ment [38] , as these marks normally accompany the parental alleles throughout the lifetime of the organism. DNA methylation, either directly or acting in concert with histone modifications and other chromosomal proteins [39] , has the capacity to determine gene activity of imprinted genes in a number of ways ( fig. 1 ). The most direct occurs where the DNA methylation mark sits on the promoter of an imprinted gene, leading to silencing of that allele. ...
Context 19
... term 'epigenetics' is used to describe this phenomenon whereby gene expression is reversibly silenced/activated independent of change to gene structure. One of the simplest models is where the DMR lies within the promoter of a gene and the methylated copy is silenced ( fig. 1 ). This is the case at the TND locus. ...
Context 20
... 6q24 there are two known imprinted genes, ZAC and HYMAI ( fig. 1 ). ZAC codes for a zinc finger protein that localises to the nucleus and is a transcription factor. ...
Context 21
... sensors were well tolerated by these small infants with no appar- ent discomfort or problems of infection or oedema at the sensor site. Using this device it was possible to demonstrate that these infants had prolonged periods of hypergly- caemia and periods of undetected hypoglycaemia ( fig. 1 ) Clinical Importance of Hyperglycaemia Recent retrospective studies have shown hyperglycaemia to be a risk factor for short- term mortality [55][56][57] and morbidities such as retinopathy of prematurity in the premature infant [58,59] . Hyperglycaemia as a marker of relative insulin deficiency may also have a significant impact on growth and metabolism in the newborn. ...

Citations

... The therapeutic margins between hypoglycemia and hyperglycemia are small, and both are harmful for neurological development of the newborn. Using an insulin pump with or without dilution of the insulin to 1:10 in 0.9% NaCl (or with a bona-fide diluent if available) can sometimes improve manageability of the insulin during the first weeks of life (35,36). Blood glucose meters must be able to give a reliable measurement of capillary blood sugar level with the smallest possible quantity of blood (e.g., 0.3 µl blood). ...
Article
Full-text available
Neonatal Diabetes (ND) mellitus is a rare genetic disease (1 in 90,000 live births). It is defined by the presence of severe hyperglycaemia associated with insufficient or no circulating insulin, occurring mainly before 6 months of age and rarely between 6 months and 1 year. Such hyperglycaemia requires either transient treatment with insulin in about half of cases, or permanent insulin treatment. The disease is explained by two major groups of mechanism: malformation of the pancreas with altered insulin-secreting cells development/survival or abnormal function of the existing pancreatic β cell. The most frequent genetic causes of neonatal diabetes mellitus with abnormal β cell function are abnormalities of the 6q24 locus and mutations of the ABCC8 or KCNJ11 genes coding for the potassium channel in the pancreatic β cell. Other genes are associated with pancreas malformation or insufficient β cells development or destruction of β cells. Clinically, compared to patients with an ABCC8 or KCNJ11 mutation, patients with a 6q24 abnormality have lower birth weight and height, are younger at diagnosis and remission, and have a higher malformation frequency. Patients with an ABCC8 or KCNJ11 mutation have neurological and neuropsychological disorders in all those tested carefully. Up to 86% of patients who go into remission have recurrent diabetes when they reach puberty, with no difference due to the genetic origin. All these results reinforce the importance of prolonged follow-up by a multidisciplinary pediatric team, and later doctors specializing in adult medicine. 90% of the patients with an ABCC8 or KCNJ11 mutation as well as those with 6q24 anomalies are amenable to a successful switch from insulin injection to oral sulfonylureas.
... In some centers in Europe, the use of CSII in all cases of neonatal diabetes mellitus is proposed, stating that during the neonatal period, CSII therapy is safe, more physiological, more accurate and easier to manage than insulin injections (15)(16)(17)(18)(19). ...
... The presence of other congenital abnormalities like pancreatic aplasia or epilepsy may also compromise normal growth. However, there is scarce information about longitudinal growth of infants with PNDM (4,18). No study assessed the growth of these infants after inulin treatment using multiple daily Injections versus CSII therapy. ...
Article
Full-text available
Background: Permanent neonatal diabetes mellitus (PNDM) is characterized by the onset of hyperglycemia within the first six months of life. Their diabetes is associated with partial or complete insulin deficiency with variable degree of intrauterine growth retardation. Insulin therapy corrects the hyperglycemia and results in improvement of growth. However, no studies have reported the longitudinal growth of these infants (head circumference, length and weight gain) after starting insulin therapy. Patients and methods: We assessed the growth parameters weight (Wt), Length (L) and head circumference (HC) in 9 infants with PNDM, during the first 2 years of their postnatal life. Five infants were on insulin pump therapy (CSII) and 4 were on multiple doses of insulin injection (MDI) therapy. Results: On insulin therapy for 20±4 months catch-up growth occurred in the majority of infants. L-SDS increased from -1.45 to -0.65 , HC-SDS from -2.3 to - 0.51 and Wt-SDS increased from -1.94 to - 0.7 at the end of the 20±4 months of age, after starting insulin therapy. Two out of 9 infants had a L-SDS <-2 , in 4 Wt-SDS was <-2 and in 1 the HC-SDS was <-2 at at 20±4 months of postnatal growth. The level of HbA1c was lower in infants on CSII compared to those on MDI (9.6±1%) compared to those on MDI (10.2±2%). However, growth parameters improved significantly in both groups (CSII and MDI) with no significant difference among them. Conclusions: Infants with PNDM with positive anti-GAD and antiTPO were diagnosed later and their intra-uterine and postnatal growth differed compared to those with negative antibodies. The majority of infants with PNDM exhibited significant catch up growth within the first two years of life irrespective of the etiology of diabetes. HbA1c appeared to be better in infants with PNDM on CSII therapy when compared to those on MDI therapy.
... İnsülin tedavisi günlük çoklu enjeksiyonlar veya devamlı subkütan infüzyon şeklinde verilebilir (55). Yenidoğan döneminde tercih edilen insülin genellikle kristalize insülindir. ...
... Parenteral beslenme veya sürekli enteral beslenme uygulanan bebeklerde insülinin total günlük dozunun sürekli bazal infüzyon şeklinde verilmesi yeterlidir (55). Anne sütü veya biberonla beslenme başladığında ise bazal insülinin toplam dozun %30'u, öğün zamanı insülinlerin ise toplam dozun %70'i olması uygundur. ...
... Anne sütü veya biberonla beslenme başladığında ise bazal insülinin toplam dozun %30'u, öğün zamanı insülinlerin ise toplam dozun %70'i olması uygundur. Günlük toplam insülin ihtiyacı 0,29 U/kg'dan 1,4 U/kg/güne kadar değişmektedir (55). Çok düşük insülin gereksinimi olduğu durumlarda (≤0.02 ...
Article
Full-text available
Neonatal diabetes is a rare cause of hyperglycemia in the neonatal period. It is caused by mutations in genes that encode proteins playing critical roles in normal functions of pancreatic beta cells. Neonatal diabetes is divided into temporary and permanent subtypes. Treatment is based on the correction of fluid-electrolyte disturbances and hyperglycemia. Patients respond to insulin or sulfonylurea treatment according to the mutation type. Close glucose monitoring and education of caregivers about diabetes are vital.
... CSII allows more precise control of small insulin doses, dilution is not necessary with some newer pumps, delivery can be adapted to feeding patterns, and parents can be taught to manage the pumps at home [22][23][24]. In addition, CSII can fairly easily be used in conjunction with continuous glucose monitoring (CGM). ...
... Many case reports of CSII in NDM (17 of 29) did not specify the type of insulin used [3,6,22,26,41,64,65]. Among those that did, most reported use of a rapid-acting insulin analogue, either insulin lispro (nine cases) [2,17,18,26,62] or insulin aspart (one case) [63]. ...
... Two cases involved CSII with soluble human insulin ( (Table 2) [3,6,22,26,41,64,65]. Total daily insulin doses ranged from 0.048-1.4 ...
Article
Aims: Neonatal diabetes mellitus (NDM) is a rare disorder, and guidance is limited regarding its optimal management. We reviewed insulin usage in NDM, with a focus on continuous subcutaneous insulin infusion (CSII). Methods: A PubMed search identified 40 reports of patients with NDM treated with insulin published between 1994 and 2016. Results: Data concerning treatment of NDM are limited. CSII resolves some of the issues associated with insulin therapy in neonates. No clinical trials of CSII in NDM have been reported. Case reports suggest that CSII is a safe and effective means of treating NDM. CSII was initiated to improve glycaemic control, for practicality and convenience, and to overcome difficulties associated with the maintenance of long-term intravenous catheters. CSII can provide better glycaemic control than multiple daily injections, with few hypoglycaemic events. Continuous glucose monitoring integrated with the pump helps provide more precise control of blood glucose levels. CSII generally uses short-acting insulin or rapid-acting insulin analogues, and those that are approved for use in neonates appear to be appropriate for the treatment of NDM using an insulin pump. Conclusions: Information from case reports indicates that CSII is safe and effective for the management of NDM.
... Intermediate-acting insulin is preferred to be given as once or twice a day therapy [4] . Initial insulin dose for stabilization may [58,59] , but the initial cost and subsequent maintenance are major issues in using insulin pumps in infants from developing countries like India. If genetic reports suggest mutations in KCNJ11 or ABCC8 mutations which are responsive to sulphonylurea, transfer to oral drugs should be undertaken. ...
Article
Infantile onset diabetes mellitus (IODM) is an uncommon metabolic disorder in children. Infants with onset of diabetes mellitus (DM) at age less than one year are likely to have transient or permanent neonatal DM or rarely type 1 diabetes. Diabetes with onset below 6 mo is a heterogeneous disease caused by single gene mutations. Literature on IODM is scanty in India. Nearly 83% of IODM cases present with diabetic keto acidosis at the onset. Missed diagnosis was common in infants with diabetes (67%). Potassium channel mutation with sulphonylurea responsiveness is the common type in the non-syndromic IODM and Wolcott Rallison syndrome is the common type in syndromic diabetes. Developmental delay and seizures were the associated co-morbid states. Genetic diagnosis has made a phenomenal change in the management of IODM. Switching from subcutaneous insulin to oral hypoglycemic drugs is a major clinical breakthrough in the management of certain types of monogenic diabetes. Mortality in neonatal diabetes is 32.5% during follow-up from Indian studies. This article is a review of neonatal diabetes and available literature on IODM from India.
... The challenges of treating diabetes in paediatric patients (neonates, young children and adolescents), the advantages of CSII over MDI in these age groups and issues surrounding the use of CSII during exercise are summarized in Table 2 [5,8,12,[47][48][49][50][51][52][53][54][55][56][57][58][59]. ...
... Paediatric patients: challenges of treating diabetes and use of CSII In neonates, CSII is safe, the subcutaneous infusion lines are well tolerated and CSII is more physiological, more accurate and easier to manage than MDI[47] Low insulin requirementAccurate dosing of small amounts of insulin is easier with CSII than with MDI[47] Little guidance is available regarding insulin dilution, but case reports describing successful dilution of insulin lispro with a compatible diluent or normal saline have been published[12,49]; insulin dilution is not necessary with the and DKA caused by erratic eating and exercise patterns Compared with MDI, CSII improves control of blood glucose fluctuations and HbA 1c ; reduces risk of hypoglycaemia and dawn phenomenon[5] In addition to its clinical advantages in young children, CSII provides improved lifestyle ...
... Paediatric patients: challenges of treating diabetes and use of CSII In neonates, CSII is safe, the subcutaneous infusion lines are well tolerated and CSII is more physiological, more accurate and easier to manage than MDI[47] Low insulin requirementAccurate dosing of small amounts of insulin is easier with CSII than with MDI[47] Little guidance is available regarding insulin dilution, but case reports describing successful dilution of insulin lispro with a compatible diluent or normal saline have been published[12,49]; insulin dilution is not necessary with the and DKA caused by erratic eating and exercise patterns Compared with MDI, CSII improves control of blood glucose fluctuations and HbA 1c ; reduces risk of hypoglycaemia and dawn phenomenon[5] In addition to its clinical advantages in young children, CSII provides improved lifestyle ...
Article
Full-text available
The level of glycaemic control necessary to achieve optimal short- and long-term outcomes in subjects with type 1 diabetes mellitus (T1DM) typically requires intensified insulin therapy using multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). For CSII, the insulins of choice are the rapid-acting insulin analogues (RAIAs), insulin aspart, insulin lispro, and insulin glulisine. Advantages of CSII over MDI in adult and paediatric populations with T1DM include superior glycaemic control, lower insulin requirements, and better health-related quality of life (HRQOL)/patient satisfaction. An association between CSII and reduced hypoglycaemic risk is more consistent in children/adolescents than in adults. Use of CSII is widely recommended in both adult and paediatric T1DM populations but is limited in pregnant patients and those with type 2 diabetes mellitus. All available RAIAs are approved for use in adult, paediatric, and pregnant populations. However, minimum patient age varies (insulin lispro: no minimum; insulin aspart: ≥2 years; insulin glulisine: ≥6 years) and experience in pregnancy ranges from extensive (insulin aspart, insulin lispro) to limited (insulin glulisine). Although more expensive than MDI, CSII is cost-effective in selected patient groups. This comprehensive review, which focuses on the European situation, summarises evidence for the efficacy and safety of CSII, particularly when used with RAIAs, in adult, paediatric, and pregnant populations, discusses relevant European guidelines, reviews issues that surround use of this technology, summarises the effects of CSII on patients' HRQOL, reviews relevant pharmacoeconomic data, and discusses recent advances in pump technology, including the development of closed-loop 'artificial pancreas' systems. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
... Since these children require such small quantities of insulin, it is advantageous to provide it with CSII, which allows administration of small amounts of insulin. [9][10][11] A historical log documents given insulin doses and stores the information, accessible for parents and professionals. 12,13 CSII therapy in young children has been proven to be safe, with good glycaemic control and few hypoglycaemias. ...
... 12,13 CSII therapy in young children has been proven to be safe, with good glycaemic control and few hypoglycaemias. [9][10][11][14][15][16] The experience of transitioning from MDI to CSII, and how this affects the quality of life of children with T1DM, has been investigated in parents, teenagers and school children. 14,[16][17][18] Fathers of children who are 2-12 years old and are transitioning from MDI to CSII viewed the latter as a smooth tool compared to the former. ...
... relevant, treatment for very young children who are insulin dependent. 4,9,10,25 Hence, the parental perspective when such young children have CSII treatment needs to be highlighted, and further research is required. ...
Article
Diabetes during infancy is uncommon and continuous subcutaneous insulin infusion (CSII) is the recommended treatment with such young children. However, this form of treatment has not been investigated previously from the perspective of the parents. The aim of this study was to determine parents' experiences of caring for a child less than two years old who had diabetes mellitus and was being treated with CSII therapy. Three pairs of parents were interviewed twice to elucidate their views on the initial period and on daily living. Data were submitted to qualitative content analysis and resulted in seven categories and one theme, the latter being: ‘The diabetes disease was threatening our baby's life, but then the insulin pump came as a rescuing, though challenging, angel’. Parents initially felt life had been turned upside down, but later they felt in control nearly all the time. It was concluded that parents of infants with diabetes are in great need of support in order to manage the disease and CSII technology. The fear of losing control and the lack of relief lead to social isolation. Educating someone close to the family could be a valuable intervention.
... Insulin can be provided by multiple daily injections or continuous subcutaneous infusion [69]. It may be necessary to use diluted insulin to meet very low insulin requirements and minimize the risk of hypoglycaemia. ...
Article
Full-text available
Over the last decade, we have witnessed major advances in the understanding of the molecular basis of neonatal and infancy-onset diabetes. It is now widely accepted that diabetes presenting before 6 months of age is unlikely to be autoimmune type 1 diabetes. The vast majority of such patients will have a monogenic disorder responsible for the disease and, in some of them, also for a number of other associated extrapancreatic clinical features. Reaching a molecular diagnosis will have immediate clinical consequences for about half of affected patients, as identification of a mutation in either of the two genes encoding the ATP-sensitive potassium channel allows switching from insulin injections to oral sulphonylureas. It also facilitates genetic counselling within the affected families and predicts clinical prognosis. Importantly, monogenic diabetes seems not to be limited to the first 6 months but extends to some extent into the second half of the first year of life, when type 1 diabetes is the more common cause of diabetes. From a scientific perspective, the identification of novel genetic aetiologies has provided important new knowledge regarding the development and function of the human pancreas.
... It is also considered a safe and well-accepted method for pediatric diabetes 14,15) . Some researchers have described the safety and efficacy of CSII in NDM 4,5,16) . However, there is no consensus on the use of insulin pump for NDM, and it is not widely used in clinical practice for treatment of NDM. ...
Article
Full-text available
Neonatal diabetes mellitus (NDM) is a rare disease requiring insulin treatment. Its treatment is primarily focused on maintaining adequate glycemic control and avoiding hypoglycemia. Although insulin pump therapy is frequently administered to adults and children, there is no consensus on the use of insulin pumps in NDM. A 10 day-old female infant was referred to us with intrauterine growth retardation and poor weight gain. Hyperglycemia was noted, and continuous intravenous insulin infusion was initiated. However, the patient's serum glucose levels fluctuated widely, and maintaining the intravenous route became difficult within the following weeks. Continuous subcutaneous insulin infusion with an insulin pump was introduced on the twenty-fifth day of life, and good glycemic control was achieved without any notable adverse effects including hypoglycemia. We suggest that the insulin pump is a safe and effective mode for treating NDM and its early adoption may shorten the length of hospital stays in patients with NDM.
... While there are limited outcomes data to drive evidence based treatment recommendations for NDM, several case series have been published. Tubina-Rufi et al. reported on their experiences in managing NDM over 18 years, and found CSII therapy to be most effective in safely managing diabetes in newborns requiring insulin for more than 15 days [6] . TNDM is most commonly associated with overexpression of the paternally inherited PLAGL1 and HYMAI genes at the 6q24 locus. ...
Article
Full-text available
Neonatal diabetes mellitus (NDM) is a rare metabolic disorder, affecting approximately 1 in 500,000 live births. The management of NDM is challenging, as the benefits of controlling hyperglycemia must be balanced with the risks of iatrogenic hypoglycemia. NDM occurs in both permanent and transient forms, which have been genetically and phenotypically well characterized. Herein, we present the previously unreported combination of transient NDM (TNDM) and congenital diaphragmatic hernia (CDH). In addition to reviewing the management and genetics of NDM we discuss the potential for overlapping genetic or embryologic abnormalities to explain the concurrence of CDH and NDM.